Cargando…
Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients
Phosphate control is still a great challenge in chronic kidney disease (CKD), and in spite of the great improvements in dialysis techniques, achievement of the goals for mineral metabolism control is still far from ideal. Aluminum hydroxide has been largely abandoned due to the high risk of aluminum...
Autor principal: | Ossareh, Shahrzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020890/ https://www.ncbi.nlm.nih.gov/pubmed/24855385 http://dx.doi.org/10.2147/IJNRD.S41626 |
Ejemplares similares
-
Sevelamer carbonate experience in Indian end stage renal disease patients
por: Abraham, G., et al.
Publicado: (2012) -
Sevelamer-Associated Rectosigmoid Ulcers in an End-Stage Renal Disease Patient
por: Uy, Pearl Princess, et al.
Publicado: (2018) -
Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients
por: Rosa-Diez, Guillermo, et al.
Publicado: (2016) -
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease
por: Rastogi, Anjay
Publicado: (2013) -
Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease
por: Lenglet, Aurelie, et al.
Publicado: (2021)